Ligand Pharmaceuticals will acquire XOMA Royalty for $39 per share, implying a total equity value of about $739 million. The deal is a significant consolidation move within biotechnology royalty aggregators and should be supportive for both companies, especially XOMA holders receiving the acquisition premium. The transaction is notable enough to influence sector sentiment and the two stocks.
Ligand Pharmaceuticals will acquire XOMA Royalty for $39 per share, implying a total equity value of about $739 million. The deal is a significant consolidation move within biotechnology royalty aggregators and should be supportive for both companies, especially XOMA holders receiving the acquisition premium. The transaction is notable enough to influence sector sentiment and the two stocks.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
